Xila-10®

Solution for injection.

Sedative and analgesic.

Horses and cattle.

Each 1 mL of solution contains:
Xylazine Hydrochloride………………………. 117 mg
(Equivalent to 100 mg of xylazine base)
Excipients c.s.p………………………………..1 mL

Xila-10®, solution for injection, produces a state of sedation accompanied by general muscle relaxation and a reduction in painful sensations. Due to its pharmacological properties, it is indicated in:

• Handling and transport of excessively nervous or aggressive animals.
• Diagnostic procedures.
• Dental procedures.
• Minor short-term surgeries, such as: cleaning and suturing wounds, removal of dermal neoplasms, etc.
• Orthopedic procedures such as depalming and shoeing.
• Pre-anesthesia in major or prolonged surgeries, with general or local anesthetics.

Slow intravenous or intramuscular administration, in a single dose.

• Dosage of the active ingredient:
  Horses: 0.6 – 1.1 mg/kg, by slow EV route.
  2.2 – 3.0 mg/kg, IM.
  Cattle: 0.05 – 0.3 mg/kg, IM.
• Product Dosage:
  Horsepower: 0.6 – 1.1 mL / 100 Kg, by slow EV.
  2.2 – 3.0 mL / 100 Kg, IM.
  Cattle: 0.05 – 0.3 mL / 100 Kg, IM.

Intravenous administration should be done slowly.
After the injection of Xila-10®, the animal should be kept at rest until the desired effect has been achieved.

• In horses, at therapeutic doses may occasionally cause mild muscle tremor, bradycardia with partial AV block, and a decrease in respiratory rate.
• In cattle, profuse salivation and rumen atony may occur.

Keep out of reach of children and pets.

• To achieve the desired effect, during the administration of the drug the animal must be calm and fasting for at least 6 hours.
• Use with caution in animals with lung conditions, hepatic or renal dysfunction, severe heart disease, shock, or under stressful conditions, such as extreme heat or cold, at altitude, fatigued.
• Keep out of reach of children and pets.

• Do not use concomitantly with adrenoreceptor stimulants (Adrenaline, Noradrenaline, Dopamine).
  
• Do not administer to animals with ventricular arrhythmias.
  
• Do not use in animals with obstructive bowel disease or intestinal impaction.
  
• Do not administer to pregnant females in the last third of gestation, except at parturition.
  
• Do not administer to lactating females.

Xylazine should not be used in combination therapy with neuroleptics or tranquilizers. The use of xylazine and barbiturates causes additive depressant effects; The use of barbiturates to induce anesthesia should be at a reduced dose level and administered slowly when injected intravenously.
Xylazine should not be used in concomitance with adrenoreceptor stimulants (Adrenaline, Noradrenaline, Dopamine).

• Wash your hands after administering the product.
• During handling of the product, do not eat, drink liquids, or smoke.
• Avoid contact with skin and eyes.
• In case of contact with the eyes, it is recommended to wash with plenty of water for 15 minutes.
• In case of accidental ingestion, call a doctor or poison control center. Do not induce vomiting.
• In case of accidental self-injection, consult a doctor immediately.

Dispose of waste of this product with caution along with household waste. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory.

Meat: 2 days. Do not administer to horses whose meat is intended for human consumption.
Milk: 2 days.

Store between 15 and 30 °C, away from light. Once opened, use within 28 days. Discard the unused product after that period of time.

Chile: Sale under prescription Withheld Veterinary Doctor.
Peru: Under prescription restricted.
Other countries: Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Ampoule bottle with 50 mL

Chile: Reg. SAG N° 1837
Rep. Dominican: Reg. N° 9102
Peru: Reg. SENASA F.79.01.I.0004
Bolivia: Reg. SENASAG PUV-N° 009991/21

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.